<< Back To Search

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT06055075
Age 18 +
Sex Both
Phase Phase 1, Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that aim to improve patient outcomes and quality of life. Here are some key details about the study:
  • The treatment involves a unique combination of therapies that have not been widely used together before.
  • Patients will receive personalized care based on their individual health needs and responses to treatment.
  • The study includes a diverse group of participants, which helps ensure that the findings are applicable to a wide range of patients.
  • Researchers are closely monitoring the effects of the treatment on both the disease and the patients' overall well-being.
  • The study aims to gather valuable data that could lead to new standards of care in treating this condition.
Overall, this study represents an innovative approach to treatment, with the potential to make a significant impact on how this type of blood cancer is managed.
Third Opinion AI Generated Synopsis

Trial Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in participants with relapsed or refractory multiple myeloma (r/r MM). The study consists of two phases: a dose exploration phase and a dose-expansion phase.
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: